Zymeworks Inc. (ZYME)
USD 12.74
(-4.71%)
USD 12.74
(-4.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -129.95 Million USD | -191.56% |
| 2022 | 147.23 Million USD | 160.53% |
| 2021 | -206.08 Million CAD | -15.02% |
| 2020 | -177.17 Million USD | -25.17% |
| 2019 | -143.19 Million USD | -352.09% |
| 2018 | -30.75 Million USD | -459.01% |
| 2017 | -6.08 Million USD | 83.66% |
| 2016 | -36.26 Million USD | -89.43% |
| 2015 | -18.62 Million USD | -52.98% |
| 2014 | -12.33 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -23.07 Million USD | 35.51% |
| 2024 Q1 | -35.77 Million USD | -70.02% |
| 2024 Q3 | -34.2 Billion USD | -13.8% |
| 2023 Q3 | -33.23 Million USD | 32.39% |
| 2023 Q1 | -27.28 Million USD | -108.54% |
| 2023 Q2 | -49.15 Million USD | -80.19% |
| 2023 FY | - USD | -191.56% |
| 2023 Q4 | -19.47 Million USD | 41.41% |
| 2022 Q2 | -64.37 Million USD | 3.91% |
| 2022 FY | - USD | 160.53% |
| 2022 Q4 | 319.39 Million USD | 743.67% |
| 2022 Q3 | -49.62 Million USD | 22.92% |
| 2022 Q1 | -66.99 Million USD | -64.0% |
| 2021 Q4 | -40.84 Million CAD | 30.78% |
| 2021 Q2 | -66.56 Million USD | -57.53% |
| 2021 FY | - CAD | -15.02% |
| 2021 Q1 | -42.25 Million USD | -12.54% |
| 2021 Q3 | -59.01 Million USD | 11.33% |
| 2020 Q2 | -37.91 Million USD | -4.5% |
| 2020 Q1 | -36.28 Million USD | 50.8% |
| 2020 Q4 | -37.54 Million USD | 47.02% |
| 2020 FY | - USD | -25.17% |
| 2020 Q3 | -70.87 Million USD | -86.91% |
| 2019 Q1 | -11.81 Million USD | -238.41% |
| 2019 FY | - USD | -352.09% |
| 2019 Q4 | -73.75 Million USD | -147.64% |
| 2019 Q3 | -29.78 Million USD | -15.23% |
| 2019 Q2 | -25.84 Million USD | -118.79% |
| 2018 Q3 | -17.38 Million USD | -1665.28% |
| 2018 Q4 | 8.53 Million USD | 149.09% |
| 2018 FY | - USD | -459.01% |
| 2018 Q1 | -19.13 Million USD | -157.4% |
| 2018 Q2 | -985 Thousand USD | 94.85% |
| 2017 Q1 | -14.31 Million USD | -42.58% |
| 2017 Q2 | -8.37 Million USD | 41.5% |
| 2017 Q3 | -15.76 Million USD | -88.26% |
| 2017 Q4 | 33.33 Million USD | 311.4% |
| 2017 FY | - USD | 83.66% |
| 2016 Q3 | -10.27 Million USD | -59.84% |
| 2016 Q2 | -6.43 Million USD | 32.36% |
| 2016 Q1 | -9.5 Million USD | -24.53% |
| 2016 FY | - USD | -89.43% |
| 2016 Q4 | -10.04 Million USD | 2.3% |
| 2015 FY | - USD | -52.98% |
| 2015 Q4 | -7.63 Million USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ADC Therapeutics SA | -146.76 Million USD | 11.451% |
| Alto Neuroscience, Inc. | -34.56 Million USD | -276.008% |
| Annovis Bio, Inc. | -45.03 Million USD | -188.567% |
| Biohaven Pharmaceutical Holding Company Ltd. | -429.13 Million USD | 69.717% |
| Ginkgo Bioworks Holdings, Inc. | -821.29 Million USD | 84.177% |
| Nuvation Bio Inc. | -99.6 Million USD | -30.478% |
| Nuvation Bio Inc. | -99.6 Million USD | -30.478% |
| Arcus Biosciences, Inc. | -283 Million USD | 54.079% |
| Theriva Biologics, Inc. | -19.85 Million USD | -554.558% |